Harnessing immune cells and antibodies to aim for an HIV cure
REACH: Research Enterprise to Advance a Cure for HIV
['FUNDING_OTHER'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-11094754
This program aims to develop treatments using immune cells and new antibody therapies so people with HIV could control or eliminate the virus without daily antiretrovirals.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11094754 on ClinicalTrials.gov |
What this research studies
Researchers at Weill Cornell and collaborators are studying how immune cells (natural killer cells and T cells) and next-generation virus-neutralizing antibodies work against HIV. They will study the hidden HIV reservoir and how these immune tools can reduce or clear it through laboratory work and by moving promising approaches toward early human testing. The program combines basic science with development of biologic therapies and pathways to clinical trials for either durable ART-free remission or eradication. If you participate, you might be asked to provide blood or tissue samples and could be invited to join early-phase treatment trials when available.
Who could benefit from this research
Good fit: Ideal candidates are adults living with HIV who are stable on antiretroviral therapy and willing to join cure-focused studies that may include blood or tissue sampling or experimental immune therapies.
Not a fit: People without HIV, those with uncontrolled or untreated HIV, or anyone unwilling to undergo experimental immune- or antibody-based interventions are unlikely to receive direct benefit from this program.
Why it matters
Potential benefit: If successful, this work could let people living with HIV stop daily ART while keeping the virus suppressed or could lead to methods that eliminate HIV reservoirs.
How similar studies have performed: There are rare cures after bone marrow transplants and several early immune- and antibody-based trials are underway, but no broadly applicable cure has yet been achieved.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JONES, R. BRAD — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: JONES, R. BRAD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus